Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma.

Détails

ID Serval
serval:BIB_39B701424A31
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma.
Périodique
European Journal of Cancer (oxford, England : 1990)
Auteur⸱e⸱s
Brandes A.A., Franceschi E., Gorlia T., Wick W., Jacobs A.H., Baumert B.G., van den Bent M., Weller M., Stupp R., On behalf of European Organisation for Research
Collaborateur⸱rice⸱s
Treatment of Cancer Brain Tumour Group
ISSN
1879-0852 (Electronic)
ISSN-L
0959-8049
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
48
Numéro
6
Pages
896-903
Langue
anglais
Notes
Publication types: JOURNAL ARTICLE
Résumé
The progression-free survival rate at 6months (PFS-6) has long been considered the best end-point for assessing the efficacy of new agents in phase II trials in patients with recurrent glioblastoma. However, due to the introduction of antiangiogenic agents in this setting, and their intrinsic propensity to alter neuroradiological disease assessment by producing pseudoregression, any end-point based on neuroradiological modifications should be reconsidered. Further, statistically significant effects on progression-free survival (PFS) only should not automatically be considered reliable evidence of meaningful clinical benefit. In this context, because of its direct and unquestionable clinical relevance, overall survival (OS) represents the gold standard end-point for measuring clinical efficacy, despite the disadvantage that it is influenced by subsequent therapies and usually takes longer time to be evaluated. Therefore, while awaiting novel imaging criteria for response evaluation and/or new imaging tools to distinguish between 'true' and 'pseudo'-responses to antiangiogenic agents, the measurement of OS or OS rates should be considered primary end-points, also in phase II trials with these agents.
Pubmed
Web of science
Création de la notice
28/04/2012 8:35
Dernière modification de la notice
20/08/2019 13:29
Données d'usage